link
Bookmarks
Anaplastic Oligodendroglioma
Karen L. Salzman, MD
To access 4,300 diagnoses written by the world's leading experts in radiology, please log in or subscribe.Log inSubscribe
0
6
10
0

KEY FACTS

  • Terminology

    • Imaging

      • Top Differential Diagnoses

        • Pathology

          • Clinical Issues

            TERMINOLOGY

            • Abbreviations

              • Anaplastic oligodendroglioma (AO), high-grade oligodendroglioma (oligo)
            • Definitions

              • Highly cellular, diffusely infiltrating glioma
              • Oligodendroglioma with focal or diffuse histologic features of malignancy

            IMAGING

            • General Features

              • CT Findings

                • MR Findings

                  • Nuclear Medicine Findings

                    • Imaging Recommendations

                      DIFFERENTIAL DIAGNOSIS

                        PATHOLOGY

                        • General Features

                          • Staging, Grading, & Classification

                            • Gross Pathologic & Surgical Features

                              • Microscopic Features

                                CLINICAL ISSUES

                                • Presentation

                                  • Demographics

                                    • Natural History & Prognosis

                                      • Treatment

                                        DIAGNOSTIC CHECKLIST

                                        • Consider

                                          • Image Interpretation Pearls

                                            Selected References

                                            1. Ahluwalia MS et al: Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study. J Neurooncol. 122(1):111-9, 2015
                                            2. Kobayashi K et al: Prognostic value of volume-based measurements on (11)C-methionine PET in glioma patients. Eur J Nucl Med Mol Imaging. 42(7):1071-80, 2015
                                            3. Speirs CK et al: Impact of 1p/19q codeletion and histology on outcomes of anaplastic gliomas treated with radiation therapy and temozolomide. Int J Radiat Oncol Biol Phys. 91(2):268-76, 2015
                                            4. Vogelbaum MA et al: Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131. J Neurooncol. ePub, 2015
                                            5. Anderson MD et al: Clinical discussion of the management of anaplastic oligodendroglioma/oligoastrocytoma (both codeleted and nondeleted). J Natl Compr Canc Netw. 12(5):665-72, 2014
                                            6. Fudaba H et al: Comparison of multiple parameters obtained on 3T pulsed arterial spin-labeling, diffusion tensor imaging, and MRS and the Ki-67 labeling index in evaluating glioma grading. AJNR Am J Neuroradiol. 35(11):2091-8, 2014
                                            7. Mangla R et al: Correlation between progression free survival and dynamic susceptibility contrast MRI perfusion in WHO grade III glioma subtypes. J Neurooncol. 116(2):325-31, 2014
                                            8. Minniti G et al: Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and prognostic value of molecular markers. J Neurooncol. 116(2):275-82, 2014
                                            9. Chawla S et al: Differentiation between oligodendroglioma genotypes using dynamic susceptibility contrast perfusion-weighted imaging and proton MR spectroscopy. AJNR Am J Neuroradiol. 34(8):1542-9, 2013
                                            10. Fellah S et al: Multimodal MR imaging (diffusion, perfusion, and spectroscopy): is it possible to distinguish oligodendroglial tumor grade and 1p/19q codeletion in the pretherapeutic diagnosis? AJNR Am J Neuroradiol. 34(7):1326-33, 2013
                                            11. Oshiro S et al: Efficacy of temozolomide treatment in patients with high-grade glioma. Anticancer Res. 29(3):911-7, 2009
                                            12. Flannery T et al: Familial occurrence of oligodendroglial tumours. Br J Neurosurg. 22(3):436-8, 2008
                                            13. Giannini C et al: Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathol. 18(3):360-9, 2008
                                            14. Iwamoto FM et al: Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas. J Neurooncol. 88(3):293-8, 2008
                                            15. Louis DN et al: WHO Classification of Tumours of the Central Nervous System: Anaplastic Oligodendroglioma. Lyon, France: IARC Press. 60-2, 2007
                                            16. Miwa K et al: Relatively decreased 11C-methionine uptake within the anaplastic component of a mixed-grade oligodendroglioma. AJNR Am J Neuroradiol. 28(10):2005-7, 2007
                                            17. Oshiro S et al: Quantitative assessment of gliomas by proton magnetic resonance spectroscopy. Anticancer Res. 27(6A):3757-63, 2007
                                            18. Spampinato MV et al: Cerebral blood volume measurements and proton MR spectroscopy in grading of oligodendroglial tumors. AJR Am J Roentgenol. 188(1):204-12, 2007
                                            19. Maia AC Jr et al: MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas. AJNR Am J Neuroradiol. 26(4):777-83, 2005
                                            20. Lev MH et al: Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. AJNR Am J Neuroradiol. 25(2):214-21, 2004
                                            21. Naugle DK et al: Oligoastrocytoma. Radiographics. 24(2):598-600, 2004
                                            22. Engelhard HH et al: Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment, and prognosis. Surg Neurol. 60(5):443-56, 2003
                                            23. McBryde CW et al: Anaplastic oligodendroglioma with metastasis to the spinal cord. Br J Neurosurg. 17(4):364-6, 2003
                                            24. Wong TZ et al: Positron emission tomography imaging of brain tumors. Neuroimaging Clin N Am. 12(4):615-26, 2002
                                            25. Derlon JM et al: Non-invasive grading of oligodendrogliomas: correlation between in vivo metabolic pattern and histopathology. Eur J Nucl Med. 27(7):778-87, 2000
                                            26. Prayson RA et al: Clinicopathologic study of forty-four histologically pure supratentorial oligodendrogliomas. Ann Diagn Pathol. 4(4):218-27, 2000
                                            27. Reifenberger G et al: Pathology and genetics of tumours of the nervous system: Oligodendroglioma. Lyon, France: IARC Press. 56-69, 2000
                                            Related Anatomy
                                            Loading...
                                            Related Differential Diagnoses
                                            Loading...
                                            References
                                            Tables

                                            Tables

                                            KEY FACTS

                                            • Terminology

                                              • Imaging

                                                • Top Differential Diagnoses

                                                  • Pathology

                                                    • Clinical Issues

                                                      TERMINOLOGY

                                                      • Abbreviations

                                                        • Anaplastic oligodendroglioma (AO), high-grade oligodendroglioma (oligo)
                                                      • Definitions

                                                        • Highly cellular, diffusely infiltrating glioma
                                                        • Oligodendroglioma with focal or diffuse histologic features of malignancy

                                                      IMAGING

                                                      • General Features

                                                        • CT Findings

                                                          • MR Findings

                                                            • Nuclear Medicine Findings

                                                              • Imaging Recommendations

                                                                DIFFERENTIAL DIAGNOSIS

                                                                  PATHOLOGY

                                                                  • General Features

                                                                    • Staging, Grading, & Classification

                                                                      • Gross Pathologic & Surgical Features

                                                                        • Microscopic Features

                                                                          CLINICAL ISSUES

                                                                          • Presentation

                                                                            • Demographics

                                                                              • Natural History & Prognosis

                                                                                • Treatment

                                                                                  DIAGNOSTIC CHECKLIST

                                                                                  • Consider

                                                                                    • Image Interpretation Pearls

                                                                                      Selected References

                                                                                      1. Ahluwalia MS et al: Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study. J Neurooncol. 122(1):111-9, 2015
                                                                                      2. Kobayashi K et al: Prognostic value of volume-based measurements on (11)C-methionine PET in glioma patients. Eur J Nucl Med Mol Imaging. 42(7):1071-80, 2015
                                                                                      3. Speirs CK et al: Impact of 1p/19q codeletion and histology on outcomes of anaplastic gliomas treated with radiation therapy and temozolomide. Int J Radiat Oncol Biol Phys. 91(2):268-76, 2015
                                                                                      4. Vogelbaum MA et al: Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131. J Neurooncol. ePub, 2015
                                                                                      5. Anderson MD et al: Clinical discussion of the management of anaplastic oligodendroglioma/oligoastrocytoma (both codeleted and nondeleted). J Natl Compr Canc Netw. 12(5):665-72, 2014
                                                                                      6. Fudaba H et al: Comparison of multiple parameters obtained on 3T pulsed arterial spin-labeling, diffusion tensor imaging, and MRS and the Ki-67 labeling index in evaluating glioma grading. AJNR Am J Neuroradiol. 35(11):2091-8, 2014
                                                                                      7. Mangla R et al: Correlation between progression free survival and dynamic susceptibility contrast MRI perfusion in WHO grade III glioma subtypes. J Neurooncol. 116(2):325-31, 2014
                                                                                      8. Minniti G et al: Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and prognostic value of molecular markers. J Neurooncol. 116(2):275-82, 2014
                                                                                      9. Chawla S et al: Differentiation between oligodendroglioma genotypes using dynamic susceptibility contrast perfusion-weighted imaging and proton MR spectroscopy. AJNR Am J Neuroradiol. 34(8):1542-9, 2013
                                                                                      10. Fellah S et al: Multimodal MR imaging (diffusion, perfusion, and spectroscopy): is it possible to distinguish oligodendroglial tumor grade and 1p/19q codeletion in the pretherapeutic diagnosis? AJNR Am J Neuroradiol. 34(7):1326-33, 2013
                                                                                      11. Oshiro S et al: Efficacy of temozolomide treatment in patients with high-grade glioma. Anticancer Res. 29(3):911-7, 2009
                                                                                      12. Flannery T et al: Familial occurrence of oligodendroglial tumours. Br J Neurosurg. 22(3):436-8, 2008
                                                                                      13. Giannini C et al: Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathol. 18(3):360-9, 2008
                                                                                      14. Iwamoto FM et al: Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas. J Neurooncol. 88(3):293-8, 2008
                                                                                      15. Louis DN et al: WHO Classification of Tumours of the Central Nervous System: Anaplastic Oligodendroglioma. Lyon, France: IARC Press. 60-2, 2007
                                                                                      16. Miwa K et al: Relatively decreased 11C-methionine uptake within the anaplastic component of a mixed-grade oligodendroglioma. AJNR Am J Neuroradiol. 28(10):2005-7, 2007
                                                                                      17. Oshiro S et al: Quantitative assessment of gliomas by proton magnetic resonance spectroscopy. Anticancer Res. 27(6A):3757-63, 2007
                                                                                      18. Spampinato MV et al: Cerebral blood volume measurements and proton MR spectroscopy in grading of oligodendroglial tumors. AJR Am J Roentgenol. 188(1):204-12, 2007
                                                                                      19. Maia AC Jr et al: MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas. AJNR Am J Neuroradiol. 26(4):777-83, 2005
                                                                                      20. Lev MH et al: Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. AJNR Am J Neuroradiol. 25(2):214-21, 2004
                                                                                      21. Naugle DK et al: Oligoastrocytoma. Radiographics. 24(2):598-600, 2004
                                                                                      22. Engelhard HH et al: Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment, and prognosis. Surg Neurol. 60(5):443-56, 2003
                                                                                      23. McBryde CW et al: Anaplastic oligodendroglioma with metastasis to the spinal cord. Br J Neurosurg. 17(4):364-6, 2003
                                                                                      24. Wong TZ et al: Positron emission tomography imaging of brain tumors. Neuroimaging Clin N Am. 12(4):615-26, 2002
                                                                                      25. Derlon JM et al: Non-invasive grading of oligodendrogliomas: correlation between in vivo metabolic pattern and histopathology. Eur J Nucl Med. 27(7):778-87, 2000
                                                                                      26. Prayson RA et al: Clinicopathologic study of forty-four histologically pure supratentorial oligodendrogliomas. Ann Diagn Pathol. 4(4):218-27, 2000
                                                                                      27. Reifenberger G et al: Pathology and genetics of tumours of the nervous system: Oligodendroglioma. Lyon, France: IARC Press. 56-69, 2000